X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (195) 195
humans (152) 152
cancer (99) 99
animals (97) 97
oncology (86) 86
cell biology (64) 64
expression (54) 54
metastasis (54) 54
microrna (53) 53
gene expression (52) 52
cell line, tumor (51) 51
biochemistry & molecular biology (45) 45
targeting ezh2 (45) 45
proteins (44) 44
genetic aspects (43) 43
female (42) 42
mice (42) 42
apoptosis (40) 40
health aspects (40) 40
micrornas - genetics (40) 40
research (40) 40
gene expression regulation, neoplastic (38) 38
development and progression (37) 37
down-regulation (36) 36
tumors (36) 36
chromatin (35) 35
male (34) 34
methylation (34) 34
care and treatment (33) 33
micrornas (33) 33
stem cells (32) 32
epigenetics (30) 30
proliferation (30) 30
signal transduction (30) 30
ezh2 (29) 29
review (29) 29
breast-cancer (28) 28
cell proliferation (28) 28
gene targeting (28) 28
cells (26) 26
kinases (26) 26
mutation (26) 26
epithelial-mesenchymal transition (25) 25
invasion (25) 25
cell growth (24) 24
dna methylation (24) 24
mirna (24) 24
transcription (24) 24
analysis (23) 23
genes (23) 23
article (22) 22
medical prognosis (22) 22
up-regulation (22) 22
growth (21) 21
pharmacology & pharmacy (21) 21
transcription factors (21) 21
cell cycle (20) 20
chemotherapy (20) 20
genomics (20) 20
prostate-cancer (20) 20
tumor-suppressor (20) 20
biology (19) 19
liver cancer (19) 19
micrornas - metabolism (19) 19
physiological aspects (19) 19
biomarkers (18) 18
biotechnology & applied microbiology (18) 18
drug resistance (18) 18
gene silencing (18) 18
genetics & heredity (18) 18
prognosis (18) 18
breast cancer (17) 17
cancer therapies (17) 17
epigenetic inheritance (17) 17
gene targeting - methods (17) 17
genomes (17) 17
macromolecular substances (17) 17
medicine, research & experimental (17) 17
stem-cells (17) 17
therapy (17) 17
activation (16) 16
drug targeting (16) 16
gene-expression (16) 16
hepatocellular-carcinoma (16) 16
prostate cancer (16) 16
rna interference (16) 16
tumorigenesis (16) 16
antineoplastic agents - pharmacology (15) 15
epigenesis, genetic (15) 15
lung-cancer (15) 15
phosphorylation (15) 15
antineoplastic agents - therapeutic use (14) 14
carcinoma (14) 14
deoxyribonucleic acid--dna (14) 14
histones - metabolism (14) 14
molecular targeted therapy (14) 14
neoplasms - genetics (14) 14
ovarian cancer (14) 14
ribonucleic acid--rna (14) 14
drug delivery systems (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Death and Differentiation, ISSN 1350-9047, 01/2017, Volume 24, Issue 1, pp. 59 - 71
EZH2 (the Enhancer of Zeste Homolog 2), as a key epigenetic regulator and EMT inducer, participates in a variety of cancer metastasis. EZH2 stability is... 
LONG NONCODING RNA | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | GROUP PROTEIN EZH2 | TARGETING EZH2 | SUPPRESSES METHYLATION | PROMOTES OSTEOGENIC DIFFERENTIATION | EPITHELIAL-MESENCHYMAL TRANSITIONS | CONTRIBUTES | CARCINOMA | HISTONE METHYLTRANSFERASE | CELL BIOLOGY | Index Medicus | Original Paper
Journal Article
Cancer Science, ISSN 1347-9032, 10/2017, Volume 108, Issue 10, pp. 2069 - 2078
Polycomb repressive complex 2 ( PRC 2) methylates histone H3 lysine 27 and represses gene expression to regulate cell proliferation and differentiation.... 
EZH | histone methyltransferase | Dual inhibitor | H3K27me3 | EZH1 | EZH2 | SWI/SNF COMPLEXES | B-CELL LYMPHOMAS | TARGETING EZH2 | SOMATIC MUTATIONS | CANCER GENOMICS | ONCOLOGY | HEMATOPOIETIC STEM-CELLS | H3 LYSINE 27 | GENE EZH2 | HISTONE METHYLTRANSFERASE EZH2 | REPRESSIVE COMPLEX 2 | Enhancer of Zeste Homolog 2 Protein - chemistry | Cell Survival - drug effects | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Small Molecule Libraries - pharmacology | Drug Screening Assays, Antitumor - methods | Administration, Oral | Humans | Models, Molecular | Rats | Biological Availability | Structure-Activity Relationship | Small Molecule Libraries - chemistry | Animals | Polycomb-Group Proteins - antagonists & inhibitors | Cell Line, Tumor | Polycomb-Group Proteins - chemistry | Cell Proliferation - drug effects | Small Molecule Libraries - pharmacokinetics | Chromatin | Methyltransferases | Lysine | Leukemia | Lung cancer | Histones | Lymphomas | Gene expression | Cell differentiation | Cell proliferation | Nuclear magnetic resonance--NMR | Sucrose | Toxicity | Methyltransferase | Colorectal cancer | Multiple myeloma | Employees | Lethality | Ovarian cancer | Tumorigenesis | Therapeutic applications | Bioavailability | Tumor cell lines | Lymphoma | Chromatin remodeling | Polycomb group proteins | AML1 protein | Lymphocytes B | Cell lines | Stem cells | Antitumor activity | Mutation | Methylation | Homocysteine | Binding sites | Histone H3 | Cancer | Tumors | Index Medicus | Original
Journal Article
Journal Article
Cell Death and Disease, ISSN 2041-4889, 02/2018, Volume 9, Issue 2, pp. 238 - 16
Aberrant expression of long noncoding RNA GAS5 in bladder cancer (BC) cells was identified in recent studies. However, the regulatory functions and underlying... 
ACTIVATION | METASTASIS | GASTRIC-CANCER | PATHWAY | UROTHELIAL CARCINOMA | TARGETING EZH2 | TUMOR-SUPPRESSOR | PROLIFERATION | EXPRESSION | PROGRESSION | CELL BIOLOGY | RNA, Small Interfering - genetics | Apoptosis - drug effects | Humans | Gene Expression Regulation, Neoplastic | Apoptosis - genetics | Male | Urinary Bladder - pathology | Xanthones - pharmacology | MicroRNAs - pharmacology | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Female | Transcription, Genetic | E2F4 Transcription Factor - metabolism | Urinary Bladder - surgery | Carcinoma, Transitional Cell - genetics | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | Signal Transduction | Urinary Bladder - metabolism | RNA, Long Noncoding - genetics | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | E2F4 Transcription Factor - genetics | Xenograft Model Antitumor Assays | Cystectomy | Animals | Carcinoma, Transitional Cell - pathology | Tumor Burden - drug effects | Mice, Nude | Carcinoma, Transitional Cell - drug therapy | Cell Line, Tumor | Urinary Bladder - drug effects | Cell Proliferation - drug effects | Mice | Carcinoma, Transitional Cell - surgery | Antineoplastic Agents, Phytogenic - pharmacology | RNA, Long Noncoding - antagonists & inhibitors | RNA, Long Noncoding - metabolism | RNA, Small Interfering - metabolism | Molecular modelling | Transcription | Ribonucleic acid--RNA | Bladder cancer | Apoptosis | Cancer | Index Medicus
Journal Article
Journal Article
by Huang, S and Wang, ZY and Zhou, J and Huang, JN and Zhou, L and Luo, J and Wan, YY and Long, HX and Zhu, B
CANCER RESEARCH, ISSN 0008-5472, 04/2019, Volume 79, Issue 8, pp. 2009 - 2020
Enhancer of zeste homolog (EZH2) is a key epigenetic regulator of gene expression and is frequently overexpressed in various cancer types, suggesting a role in... 
METHYLATION | ACTIVATION | ONCOLOGY | CHEMOKINES | TARGETING EZH2 | TUMOR | DIFFERENTIATION | C/EBP-EPSILON | CANCER | T-CELLS | PROGRESSION
Journal Article
Oncogene, ISSN 0950-9232, 06/2018, Volume 37, Issue 26, pp. 3589 - 3600
Journal Article
Cell Cycle, ISSN 1538-4101, 11/2018, Volume 17, Issue 21-22, pp. 2460 - 2473
Rottlerin as a natural agent, which is isolated from Mallotus philippinensis, has been identified to play a critical role in tumor inhibition. However, the... 
cell growth | prostate cancer | cell invasion | Rottlerin | EZH2 | DELTA-INDEPENDENT PATHWAY | APOPTOSIS | STEM-CELLS | CARCINOMA CELLS | TARGETING EZH2 | AUTOPHAGY | KINASE-ASSOCIATED PROTEIN-2 | CELL BIOLOGY | BREAST-CANCER | PKC-DELTA | UP-REGULATION
Journal Article
Cellular Physiology and Biochemistry, ISSN 1015-8987, 10/2018, Volume 49, Issue 4, pp. 1615 - 1632
Background/Aims: We previously showed that the major bioactive compound of Atractylodes macrocephula Koidz atractylenolide 1 (ATL-1) inhibited human lung... 
Original Paper | HOTAIR | Atractylenolide 1 | Erlotinib | Human lung cancer cells | EZH2 | PDK1 | PHYSIOLOGY | METASTASIS | DOWN-REGULATION | TARGETING EZH2 | PROLIFERATION | E-CADHERIN | ACTIVATING EGFR MUTATIONS | CELL BIOLOGY | LONG NONCODING RNA | GASTRIC-CANCER | RESISTANCE | PROMOTES | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Lactones - pharmacology | Sesquiterpenes - therapeutic use | RNA Interference | Female | Gene Expression Regulation, Neoplastic - drug effects | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | 3-Phosphoinositide-Dependent Protein Kinases - genetics | RNA, Long Noncoding - genetics | 3-Phosphoinositide-Dependent Protein Kinases - antagonists & inhibitors | 3-Phosphoinositide-Dependent Protein Kinases - metabolism | Lactones - therapeutic use | Animals | Cell Cycle Checkpoints - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Erlotinib Hydrochloride - therapeutic use | Mice | Protein Kinase Inhibitors - pharmacology | Sesquiterpenes - pharmacology | RNA, Long Noncoding - antagonists & inhibitors | RNA, Long Noncoding - metabolism | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 05/2018, Volume 138, Issue 5, pp. 1126 - 1136
Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ anaplastic large T cells, comprises the second most common group of cutaneous T-cell... 
OVEREXPRESSION | SUPPRESSOR | OXIDATIVE STRESS | INHIBITION | TRANSLOCATIONS | THIOREDOXIN | CHEMOKINES | TARGETING EZH2 | MUTATIONS | EXPRESSION | DERMATOLOGY | Index Medicus
Journal Article